Prashantha Nagaraja

Dr. Prashantha Nagaraja

orcid

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 March 2020 in Journal of Biomolecular Structure and Dynamics
Verified
Journal Article
Closed access
AHAdhikesavan Harikrishnan
Adhikesavan Harikrishnan
VVVK Veena
VK Veena
BLB. Lakshmi
B. Lakshmi
RSR. Shanmugavalli
R. Shanmugavalli
STSonia Theres
Sonia Theres
SNSisir Nandi
Sisir Nandi
Atranorin (ATR), lichenized secondary metabolite and depside molecule with several biological potentials such as antimicrobial, anticancer, anti-inflammatory, antinociceptive, wound healing and photoprotective activities. Cytotoxic reports of ATR are documented in several cancer cells and in vivo models but its molecular interaction studies are poorly understood. Therefore, in this present investigation, we have used the in silico studies with biological validation of the molecular targets for the anti-breast cancer mechanism of ATR. The molecular docking studies with the breast cancer oncoproteins such as Bcl-2, Bax, Akt, Bcl-w and Bcl-xL revealed the highest interaction was observed with the Akt followed by Bax, Bcl-xL and Bcl-2 & least with the Bcl-w proteins. The cytotoxicity studies showed ATR selectively inhibited MDA MB-231 and MCF-7 breast cancer cells in differential and dose-dependent manner with the IC50 concentration of 5.36 ± 0.85 μM and 7.55 ± 1.2 μM respectively. Further mechanistic investigations revealed that ATR significantly inhibited ROS production and significantly down-regulated the anti apoptotic Akt than Bcl-2, Bcl-xL and Bcl-w proteins with a significant increase in the Bax level and caspases-3 activity in the breast cancer cells when comparison with Akt inhibitor, ipatasertib. In vitro biological activities well correlated with the molecular interaction data suggesting that atranorin had higher interaction with Akt than Bax and Bcl-2 but weak interaction with Bcl-w and Bcl-xL. In this present study, the first time we report the interactions of atranorin with molecular targets for anti-breast cancer potential. Hence, ATR represents the nature-inspired molecule for pharmacophore moiety for design in targeted therapy.

1 January 2021 in Journal of Molecular Graphics and Modelling
Verified
Journal Article
Closed access
PNPrashantha Nagaraja
Prashantha Nagaraja
KGK. Gouthami
K. Gouthami
LLL. Lavanya
L. Lavanya
SBSivaramireddy Bhavanam
Sivaramireddy Bhavanam
AJAjay Jakhar
Ajay Jakhar
RRR. Ramachandra
R. Ramachandra

1 March 2018 in Gene Reports
Verified
Journal Article
Closed access
NPNavaneethakrishnan Polachi
Navaneethakrishnan Polachi
Boopathi SubramaniyanBoopathi Subramaniyan
Boopathi Subramaniyan
PNPrashantha Nagaraja
Prashantha Nagaraja
KRKannan Rangiah
Kannan Rangiah
MGMathan Ganeshan
Mathan Ganeshan

1 January 2019 in Journal of Natural Science, Biology and Medicine
Verified
Journal Article
Closed access
PDF file
VPVenkataraman Prabhu
Venkataraman Prabhu
BDBindu Damodaran
Bindu Damodaran
PNPrashantha Nagaraja
Prashantha Nagaraja
VJVivek Jain
Vivek Jain
MWMp Manuja Viraj Wimalasiri
Mp Manuja Viraj Wimalasiri
GKG Vinoth Kumar
G Vinoth Kumar
Background: Cancer is mostly managed by surgical removal, chemotherapy, and radiotherapy. However, there are side effects associated with these methods. Alternatively, herbal medicines are becoming popular for cancer treatment. Calotropis gigantea is a widely used plant in the traditional medical system. However, there are no reports on its potential in cancer management. Therefore, we aimed to examine the phytochemical composition and cytotoxic activity of C. gigantea methanolic leaf extract against three different cancer cell lines: HeLa (cervical), MCF7 (breast), and A549 (lung). Materials and Methods: The methanolic extract of C. gigantea leaf was used to determine the presence of phytoconstituents using standard methods such as thin-layer chromatography, high-performance liquid chromatography, and liquid chromatography–mass spectrometry. HeLa, MCF7, and A549 cell lines were treated with C. gigantea methanolic leaf extract at different concentrations (0, 100, 200, 300, and 400 μg/mL). Camptothecin and cisplatin were used as reference drugs for growth inhibition studies. Results: The phytoconstituents of methanolic leaf extract of C. gigantea included alkaloids, steroids, terpenoids, flavonoids, tannins, and phenols. The extract exhibited cytotoxicity against HeLa (IC50= 117.92 μg/mL), MCF7 (IC50= 43.65 μg/mL), and A549 (IC50= 27.32 μg/mL) cancer cell lines in vitro. Conclusion: Our results indicated that C. gigantea exhibited cytotoxicity against cervical, breast, and lung cancer cell lines in vitro, and thus, the crude extract can be a potential candidate for cancer treatment.

30 January 2020 in International Journal of Innovative Technology and Exploring Engineering
Verified
Journal Article
Closed access
NRNisha Rajasekhar
Nisha Rajasekhar
RNRamesh N
Ramesh N
PNPrashantha Nagaraja
Prashantha Nagaraja
Cancer has a major impact on society having the highest morbidity and mortality rate. Approximately 70% of deaths are predominantly caused due to cancer and it prevails in low and middle-income countries, as they are unaware of the signs and symptoms, treatment methods, non-availability of cancer drugs and the incurrence of huge economic burden on the family. As per the literature, the chemotherapeutic drug has numerous side effects and occasionally it may lead to death. Based on these inferences, there is a requirement to identify therapeutic peptides that are more effective for cancer treatment with less toxic effects on the body. Peptides have a great advantage to fight against the disease efficiently. Several flies have anticancer, antibacterial, antifungal and antioxidant properties that help to control disease and inhibit cancer progression. In the present research, we have utilized Hermetia illucens has great anticancer peptides that can control cancer growth. In the current research, we utilized crude protein extraction from Hermetia illucens larvae, to discover the inhibitory activity against MCF7 and HeLa cell lines. by adopting the MTT assay method, along with reference drug Camptothecin. Bradford assay results helped to identify that 23.5μg/ml concentration of protein is present in the crude sample. Flow cytometry was used to calculate the % of cell violations and IC50 values were observed in HeLa (19.88±50.3μg/mL) and MCF7 (224.68±50.3μg/mL) cells. Cell cycle inhibition was observed in HeLa cells of G1 (57.3±1.2) and, S (19.8±1.3) phase of dose-dependent with the significance of (P<0.05). Hermetia illucens crude protein has significant inhibition with HeLa cells that have the best anti-cancer proteins in human cervical carcinoma cells.

6 January 2020 in International Journal of Peptide Research and Therapeutics
Verified
Journal Article
Closed access
PDF file
KKKumar KM
Kumar KM
BKBURRANBOINA KUMAR
BURRANBOINA KUMAR
GRG. B. Manjunatha Reddy
G. B. Manjunatha Reddy
SASunil Abraham
Sunil Abraham
RYRevanaiah Yogisharadhya
Revanaiah Yogisharadhya
PNPrashantha Nagaraja
Prashantha Nagaraja